Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Authors
Kerns, S. L.Amidon Morlang, A.
Lee, S. M.
Peterson, D. R.
Marples, B.
Zhang, H.
Bylund, K.
Rosenzweig, D.
Hall, W.
De Ruyck, K.
Rosenstein, B. S.
Stock, R. G.
Gómez-Caamaño, A.
Vega, A.
Sosa-Fajardo, P.
Taboada-Valladares, B.
Aguado-Barrera, M. E.
Parker, C.
Veldeman, L.
Fonteyne, V.
Bultijnck, R.
Talbot, C. J.
Symonds, R. P.
Johnson, K.
Rattay, T.
Webb, A.
Lambrecht, M.
de Ruysscher, D.
Vanneste, B.
Choudhury, Ananya
Elliott, R. M.
Sperk, E.
Herskind, C.
Veldwijk, M. R.
Rancati, T.
Avuzzi, B.
Valdagni, R.
Azria, D.
Farcy Jacquet, M. P.
Chang-Claude, J.
Seibold, P.
West, Catharine M L
Janelsins, M.
Chen, Y.
Messing, E.
Morrow, G.
Affiliation
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States. Electronic address: sarah_kerns@urmc.rochester.edu. Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States. Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, United States. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, United States. Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States. Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Santiago de Compostela, Spain. Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain. Department of Uro-oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom. Leicester Cancer Research Centre, University of Leicester, United Kingdom. Department of Genetics and Genome Biology, University of Leicester, United Kingdom. KU Leuven, Radiation Oncology, Leuven, Belgium. KU Leuven, Radiation Oncology, Leuven, Belgium; Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands. Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands. Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy. Department of Radiation Oncology, Montpellier Cancer Institute, Université Montpellier, Inserm U1194, France. ICG Cancer Institute, Centre Hospitalier Universitaire de Nîmes, Nimes, France. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Department of Surgery, University of Rochester Medical Center, Rochester, United States. Department of Urology, University of Rochester Medical Center, Rochester, United States.Issue Date
2022
Metadata
Show full item recordAbstract
Background and purpose Genome-wide association studies (GWAS) of late hematuria following prostate cancer radiotherapy identified single nucleotide polymorphisms (SNPs) near AGT, encoding angiotensinogen. We tested the hypothesis that patients taking angiotensin converting enzyme inhibitors (ACEi) have a reduced risk of late hematuria. We additionally tested genetically-defined hypertension. Materials and methods Prostate cancer patients undergoing potentially-curative radiotherapy were enrolled onto two multi-center observational studies, URWCI (N = 256) and REQUITE (N = 1,437). Patients were assessed pre-radiotherapy and followed prospectively for development of toxicity for up to four years. The cumulative probability of hematuria was estimated by the Kaplan-Meier method. Multivariable grouped relative risk models assessed the effect of ACEi on time to hematuria adjusting for clinical factors and stratified by enrollment site. A polygenic risk score (PRS) for blood pressure was tested for association with hematuria in REQUITE and our Radiogenomics Consortium GWAS. Results Patients taking ACEi during radiotherapy had a reduced risk of hematuria (HR 0.51, 95%CI 0.28 to 0.94, p = 0.030) after adjusting for prior transurethral prostate and/or bladder resection, heart disease, pelvic node radiotherapy, and bladder volume receiving 70 Gy, which are associated with hematuria. A blood pressure PRS was associated with hypertension (odds ratio per standard deviation 1.38, 95%CI 1.31 to 1.46, n = 5,288, p < 0.001) but not hematuria (HR per standard deviation 0.96, 95%CI 0.87 to 1.06, n = 5,126, p = 0.41). Conclusions Our study is the first to show a radioprotective effect of ACEi on bladder in an international, multi-site study of patients receiving pelvic radiotherapy. Mechanistic studies are needed to understand how targeting the angiotensin pathway protects the bladder.Citation
Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, et al. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Vol. 168, Radiotherapy and Oncology. Elsevier BV; 2022. p. 75–82.Journal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2022.01.014PubMed ID
35077710Additional Links
https://dx.doi.org/10.1016/j.radonc.2022.01.014Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2022.01.014
Scopus Count
Collections
Related articles
- Predicting the germline dependence of hematuria risk in prostate cancer radiotherapy patients.
- Authors: Oh JH, Lee S, Thor M, Rosenstein BS, Tannenbaum A, Kerns S, Deasy JO
- Issue date: 2023 Aug
- Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.
- Authors: Kerns SL, Dorling L, Fachal L, Bentzen S, Pharoah PD, Barnes DR, Gómez-Caamaño A, Carballo AM, Dearnaley DP, Peleteiro P, Gulliford SL, Hall E, Michailidou K, Carracedo Á, Sia M, Stock R, Stone NN, Sydes MR, Tyrer JP, Ahmed S, Parliament M, Ostrer H, Rosenstein BS, Vega A, Burnet NG, Dunning AM, Barnett GC, West CM, Radiogenomics Consortium
- Issue date: 2016 Aug
- Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
- Authors: Zapatero A, Roch M, Büchser D, Castro P, Fernández-Banda L, Pozo G, Liñán O, Martin de Vidales C, Cruz-Conde A, García-Vicente F
- Issue date: 2017 Sep
- No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity.
- Authors: Barnett GC, Kerns SL, Dorling L, Fachal L, Aguado-Barrera ME, Martínez-Calvo L, Jandu HK, Welsh C, Tyrer J, Coles CE, Haviland JS, Parker C, Gómez-Caamaño A, Calvo-Crespo P, Sosa-Fajardo P, Burnet NG, Summersgill H, Webb A, De Ruysscher D, Seibold P, Chang-Claude J, Talbot CJ, Rattay T, Parliament M, De Ruyck K, Rosenstein BS, Pharoah PDP, Dunning AM, Vega A, West CML, RGC and REQUITE Consortia
- Issue date: 2022 Nov 1
- Prevention of Radiation-Induced Bladder Injury: A Murine Study Using Captopril.
- Authors: Groves AM, Paris N, Hernady E, Johnston CJ, Aljitawi O, Lee YF, Kerns SL, Marples B
- Issue date: 2023 Mar 15